Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revolution Medicines reports positive clinical progress and financial stability

Revolution Medicines made significant strides in clinical development and financial stability, despite anticipating increased expenses in 2023
Confidence in the efficacy and tolerability of RMC-6236 and RMC-6291, with a focus on optimizing dosing strategies for future development
Challenges include financial projections for 2023, patient evaluation discrepancies, and the need for more data on dose levels and response rates
Opportunities lie in exploring intermittent dosing, discussing specific response rates, and further data collection for dose optimization

Revolution Medicines reports promising antitumor activity and strengthens financial position

Revolution Medicines showcased progress in their innovative inhibitor programs, bolstered by a successful equity offering. While facing competition and addressing analyst concerns, the company is poised to deliver significant clinical updates and expand their data set for future growth.

Revolution Medicines reports Q2 progress, acquires EQRx for growth

Revolution Medicines showcased financial strength, pipeline progress, and strategic acquisitions, positioning the company for future growth.
While facing challenges in managing expenses and advancing drug candidates, opportunities in pivotal trials and partnerships present avenues for success.
Overall, Revolution Medicines remains optimistic about its clinical developments and financial stability, signaling a promising trajectory in the biopharmaceutical sector.

Revolution Medicines reports strong Q3 results and strategic investment plans

Revolution Medicines showcased promising drug results, bolstered its financial position through an acquisition, and emphasized strategic spending for value creation. Analyst inquiries highlighted the importance of clear communication and effective financial planning for future success.

Revolution Medicines reports robust 2023 performance and strategic growth

Revolution Medicines showcased strong financial performance and progress in 2023.
The company faces challenges in revenue and net loss but sees opportunities in global partnerships and drug combinations.
Strategic priorities for 2024 focus on advancing RAS inhibitors and expanding reach.
Overall, Revolution Medicines is positioned for growth despite facing financial and developmental challenges.

Revolution Medicines advances pivotal cancer trials amidst financial projections

Revolution Medicines is well-capitalized and focused on advancing key therapies.
Facing financial challenges but exploring partnerships and business growth.
Opportunities lie in expanding RMC-6236's efficacy and exploring new indications.

Revolution Medicines excels in Q2 with RAS(ON) inhibitor progress

Revolution Medicines' Q2 performance reflects strong advancements in oncology treatments, supported by a solid financial position and strategic leadership decisions.
While facing challenges in trial execution and financial management, the company's focus on innovation and growth presents significant opportunities for expansion.
Overall, Revolution Medicines is well-positioned to capitalize on the potential of its RAS(ON) inhibitor pipeline and drive future success in the biopharmaceutical industry.

Revolution Medicines reports Q3 loss but shows promise in cancer treatments

Revolution Medicines showcased progress in cancer treatments despite a net loss in Q3 2024. Strong cash reserves, promising data, and strategic collaborations position the company for future growth. Clear communication on financial strategies and upcoming milestones will be crucial for investor confidence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

Underwriters' full exercise of option brings gross proceeds to $345.0 million Underwriters' full exercise of option brings gross proceeds to $345.0 million

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 13,636,364 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,045,454 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be $300.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 7, 2023, subject to customary closing conditions.

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman, President and Chief Executive Officer Steve Kelsey - President of Research and Development Jack Anders - Chief Financial Officer Conference Call Participants Faisal Khurshid - SVB Securities Michael Schmidt - Guggenheim Partners Marc Frahm - Cowen and Company, LLC Eric Joseph - JPMorgan Chase & Co. Benjamin Burnett - Stifel Financial Corp. Alec Stranahan - Bank of America Merrill Lynch Ami Fadia - Needham & Company Jay Olson - Oppenheimer & Co. Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 Year-End 2022 Earnings Conference Call.

Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice

Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE:PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ:GERN), vice president of oncology at Genentech (part of the Roche Group) and medical director at Pharmacia / SUGEN (acquired by Pfizer). Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent®, Perjeta®, Kadcycla®, Erivedge® and imetelstat.

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy. The company is well-capitalized to continue operations and clinical advancements.

Revolution Medicines: Highly Differentiated Offering Gaining Traction

Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi's Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance & Principal Accounting Officer Steve Kelsey - President of R&D Conference Call Participants Alec Stranahan - Bank of America Faisal Khurshid - SVB Securities Eric Joseph - JPMorgan Marc Frahm - Cowen Michael Schmidt - Guggenheim Partners Chris Shibutani - Goldman Sachs Jay Olson - Oppenheimer Operator Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.

Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

KRAS G12C (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRAS G12C mutation

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor

Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants David Arrington - SVP of IR and Corporate Affairs Mark Goldsmith - Chairman and CEO Jack Anders - SVP, Finance and Principal Accounting Officer Steve Kelsey - President, Research and Development Conference Call Participants Marc Frahm - Cowen & Company Alec Stranahan - Bank of America Jonathan Chang - SVB Securities Neil Carnahan - Stifel Noah Eisenberg - JPMorgan Chase Operator Good day. My name is Christie, and I'll be your conference facilitator today.

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q2 2022 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates

First two RAS(ON) Inhibitor drug candidates advance into clinical development

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

Underwriters' full exercise of option brings gross proceeds to $264.5 million Underwriters' full exercise of option brings gross proceeds to $264.5 million

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share. Revolution Medicines says the .

News for Revolution Medicines Stock (RVMD)